FDA WARNING_LETTER - Tonic Therapeutic Herb Shop & Elixir Bar - September 28, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On September 29, 2020, the FDA and FTC issued a Warning Letter to Tonic Herb Shop regarding unapproved and misbranded products related to COVID-19. The agencies reviewed the company's website, tonicherbshop.com, on September 17 and 28, 2020, and found that it offered various herbal products claiming to mitigate, prevent, treat, diagnose, or cure COVID-19.
These products are considered unapproved new drugs under section 505(a) of the FD&C Act (21 U.S.C. § 355(a)) and misbranded drugs under section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) of the FD&C Act (21 U.S.C. § 331(a) and (d)). The letter emphasizes the public health emergency declared for COVID-19.
Tonic Herb Shop is required to immediately cease selling these unapproved and unauthorized products. Within 48 hours, the company must email COVID-19-Task-Force-CDER@fda.hhs.gov, detailing corrective actions, steps to prevent recurrence, and supporting documentation. Failure to comply may result in legal action, including seizure and injunction. The
ID · d0fced57-098b-4af9-a0d2-60c17257db09
Full citation text and observation details available on the Dashboard.